Clinical Trial: HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors

U.S., Sept. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07800936) titled 'HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors' on Aug. 26.

Brief Summary: This study is an open-label, dose-escalation and expansion, Phase I clinical study to evaluate the safety, tolerability, PK characteristics and preliminary antitumor activity of HP007 monotherapy in patients with advanced malignant solid tumors.

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: Solid Tumors

Intervention: DRUG: HP007

Participate will recepit HP007 monotherpy with 4 dose groups

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Parr Biotechnology (Hebei) Co., Ltd.

Disclaimer: Curated by HT Syndication....